Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 8.79% to 9.90%. This change in substantial holding reflects a strategic move by Allan Gray Australia, potentially impacting the company’s shareholder dynamics and signaling confidence in the company’s market position.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, focusing on providing pathology services. The company is known for its diagnostic testing services and plays a significant role in the Australian healthcare market.
Average Trading Volume: 1,018,596
Technical Sentiment Signal: Sell
Current Market Cap: A$547.9M
Learn more about ACL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue